ClinicaliQ Trial Snapshot
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma — Active Not Recruiting • Phase II • NCT05951959.
- TrAVeRse Trial Summary.
- Acalabrutinib, venetoclax and rituximab combination therapy for untreated mantle cell lymphoma, testing whether maintenance treatment improves outcomes.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
TrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation. Participants who progress during observation may receive retreatment with acalabrutinib Conditions: Mantle Cell Lymphoma (MCL) Interventions: Acalabrutinib, Venetoclax, Rituximab Lead Sponsor: AstraZeneca Planned Enrollment: 108 participants